Literature DB >> 33641552

Emerging therapeutic targets for sepsis.

Elizabeth W Tindal1, Brandon E Armstead1, Sean F Monaghan1, Daithi S Heffernan1, Alfred Ayala1.   

Abstract

Introduction: Sepsis is characterized by a dysregulated host response to infection. Sepsis-associated morbidity/mortality demands concerted research efforts toward therapeutic interventions which are reliable, broadly effective, and etiologically based. More intensive and extensive investigations on alterations in cellular signaling pathways, gene targeting as a means of modifying the characteristic hyper and/or hypo-immune responses, prevention through optimization of the microbiome, and the molecular pathways underlying the septic immune response could improve outcomes.] Areas covered: The authors discuss key experimental mammalian models and clinical trials. They provide an evaluation of evolving therapeutics in sepsis and how they have built upon past and current treatments. Relevant literature was derived from a PubMed search spanning 1987-2020.Expert opinion: Given the complex nature of sepsis and the elicited immune response, it is not surprising that a single cure-all therapeutic intervention, which is capable of effectively and reliably improving patient outcomes has failed to emerge. Innovative approaches seek to address not only the disease process but modify underlying patient factors. A true improvement in sepsis-associated morbidity/mortality will require a combination of unique therapeutic modalities.

Entities:  

Keywords:  Checkpoint proteins; epigenetics; immunosuppression; inflammation; microbiome; sepsis

Mesh:

Year:  2021        PMID: 33641552      PMCID: PMC8122062          DOI: 10.1080/14728222.2021.1897107

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  92 in total

1.  Association of Corticosteroid Treatment With Outcomes in Adult Patients With Sepsis: A Systematic Review and Meta-analysis.

Authors:  Fang Fang; Yu Zhang; Jingjing Tang; L Dade Lunsford; Tiangui Li; Rongrui Tang; Jialing He; Ping Xu; Andrew Faramand; Jianguo Xu; Chao You
Journal:  JAMA Intern Med       Date:  2019-02-01       Impact factor: 21.873

2.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.

Authors:  C J Fisher; J M Agosti; S M Opal; S F Lowry; R A Balk; J C Sadoff; E Abraham; R M Schein; E Benjamin
Journal:  N Engl J Med       Date:  1996-06-27       Impact factor: 91.245

3.  Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients.

Authors:  Caroline Guignant; Alain Lepape; Xin Huang; Hakim Kherouf; Laure Denis; Françoise Poitevin; Christophe Malcus; Aurélie Chéron; Bernard Allaouchiche; François Gueyffier; Alfred Ayala; Guillaume Monneret; Fabienne Venet
Journal:  Crit Care       Date:  2011-03-21       Impact factor: 9.097

4.  Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia.

Authors:  Y Fong; K J Tracey; L L Moldawer; D G Hesse; K B Manogue; J S Kenney; A T Lee; G C Kuo; A C Allison; S F Lowry
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

Review 5.  Animal models of sepsis.

Authors:  Mitchell P Fink
Journal:  Virulence       Date:  2013-08-19       Impact factor: 5.882

6.  Early goal-directed therapy in the management of severe sepsis or septic shock in adults: a meta-analysis of randomized controlled trials.

Authors:  Ling Zhang; Guijun Zhu; Li Han; Ping Fu
Journal:  BMC Med       Date:  2015-04-03       Impact factor: 8.775

7.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

8.  Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial.

Authors:  Colleen R Kelly; Alexander Khoruts; Christopher Staley; Michael J Sadowsky; Mortadha Abd; Mustafa Alani; Brianna Bakow; Patrizia Curran; Joyce McKenney; Allison Tisch; Steven E Reinert; Jason T Machan; Lawrence J Brandt
Journal:  Ann Intern Med       Date:  2016-08-23       Impact factor: 25.391

9.  Epidemiology and Costs of Sepsis in the United States-An Analysis Based on Timing of Diagnosis and Severity Level.

Authors:  Carly J Paoli; Mark A Reynolds; Meenal Sinha; Matthew Gitlin; Elliott Crouser
Journal:  Crit Care Med       Date:  2018-12       Impact factor: 7.598

10.  Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.

Authors:  Johanna Hansen; Alina Baum; Kristen E Pascal; Vincenzo Russo; Stephanie Giordano; Elzbieta Wloga; Benjamin O Fulton; Ying Yan; Katrina Koon; Krunal Patel; Kyung Min Chung; Aynur Hermann; Erica Ullman; Jonathan Cruz; Ashique Rafique; Tammy Huang; Jeanette Fairhurst; Christen Libertiny; Marine Malbec; Wen-Yi Lee; Richard Welsh; Glen Farr; Seth Pennington; Dipali Deshpande; Jemmie Cheng; Anke Watty; Pascal Bouffard; Robert Babb; Natasha Levenkova; Calvin Chen; Bojie Zhang; Annabel Romero Hernandez; Kei Saotome; Yi Zhou; Matthew Franklin; Sumathi Sivapalasingam; David Chien Lye; Stuart Weston; James Logue; Robert Haupt; Matthew Frieman; Gang Chen; William Olson; Andrew J Murphy; Neil Stahl; George D Yancopoulos; Christos A Kyratsous
Journal:  Science       Date:  2020-06-15       Impact factor: 47.728

View more
  3 in total

1.  Electroacupuncture pre-treatment alleviates sepsis-induced cardiac inflammation and dysfunction by inhibiting the calpain-2/STAT3 pathway.

Authors:  Xuqing Li; Li Wang; Xinwang Ying; Yujun Zheng; Qianqian Tan; Xiaolan Yu; Jiahong Gong; Ming Li; Xiaofeng Deng; Guanhu Yang; Shengcun Li; Songhe Jiang
Journal:  Front Physiol       Date:  2022-09-07       Impact factor: 4.755

Review 2.  Oncology Drug Repurposing for Sepsis Treatment.

Authors:  Izabela Rumienczyk; Maria Kulecka; Małgorzata Statkiewicz; Jerzy Ostrowski; Michal Mikula
Journal:  Biomedicines       Date:  2022-04-17

3.  Mucin 1 Inhibits Ferroptosis and Sensitizes Vitamin E to Alleviate Sepsis-Induced Acute Lung Injury through GSK3β/Keap1-Nrf2-GPX4 Pathway.

Authors:  Yu-Ming Wang; Fang-Chen Gong; Xing Qi; Yan-Jun Zheng; Xiang-Tao Zheng; Ying Chen; Zhi-Tao Yang; En-Qiang Mao; Er-Zhen Chen
Journal:  Oxid Med Cell Longev       Date:  2022-07-21       Impact factor: 7.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.